What is Leucid Bio?
Leucid Bio, headquartered in London, United Kingdom, is a pioneering cell therapy company dedicated to developing novel treatments for patients with solid tumors. Leveraging its proprietary engine, the company focuses on creating chimeric antigen receptor T cell (CAR T) therapies for individuals facing limited or no treatment options. The company's innovative approach positions it at the forefront of advanced oncology treatments, aiming to address critical unmet medical needs in a challenging therapeutic area.
How much funding has Leucid Bio raised?
Leucid Bio has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2021): $16M with participation from Epidarex Capital, Vulpes Investment Management, Future Fund, and 2Invest
Key Investors in Leucid Bio
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm specializing in building breakthrough life science companies. They act as trusted partners to founders, focusing on early-stage investments in innovative biopharmaceutical companies.
Vulpes Investment Management
Vulpes Investment Management is an opportunistic alternative investment manager focused on long-term value creation. They employ a patient investment approach, prioritizing sustainable capital appreciation across various sectors, including life sciences.
Future Fund
Future Fund, established in 2006, invests for the benefit of future generations of Australians. The fund aims to meet unfunded public sector superannuation liabilities and supports compelling investment strategies.
What's next for Leucid Bio?
The recent major strategic investment provides Leucid Bio with substantial capital to advance its pipeline of cell therapies. This financing is expected to fuel further research and development, potentially enabling the company to move its CAR T therapies closer to clinical trials and eventual market approval. The backing from prominent investors signals strong confidence in Leucid Bio's technology and its potential to disrupt the treatment of solid tumors, marking a pivotal stage in its growth trajectory.
See full Leucid Bio company page
